Skip to main content
INDV
NASDAQ Life Sciences

Indivior Reports Strong Q1 Results, Raises Full-Year 2026 Guidance, and Executes Share Buyback

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$37.8
Mkt Cap
$4.164B
52W Low
$10.63
52W High
$38
52W Position info
256% above low
Off High info
at 52W high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

INDV has more than doubled off its 52-week low of $10.63.

Summary

Indivior reported strong Q1 2026 financial results, including a 19% YoY revenue increase and 112% YoY Adjusted EBITDA growth, leading to a significant raise in its full-year 2026 guidance. The company also repurchased $125 million in shares and completed a $500 million convertible notes offering, while discontinuing two pipeline programs.


Key Events · Earnings and Guidance · INDV

  • Strong Q1 Financial Performance

    Indivior reported Q1 2026 total net revenue of $317 million, up 19% year-over-year, driven by a 32% increase in SUBLOCADE net revenue to $232 million. Adjusted EBITDA surged 112% year-over-year to a record $164 million.

  • Raised Full-Year 2026 Guidance

    The company raised its full-year 2026 guidance, now expecting total net revenue between $1,215 million and $1,285 million, and Adjusted EBITDA between $620 million and $660 million, representing a significant increase from prior estimates.

  • Significant Share Repurchase

    Indivior repurchased approximately 4 million shares for $125 million during Q1 2026, with $275 million remaining under its $400 million share repurchase program authorized in February 2026.

  • Pipeline Adjustments

    The company announced it will not pursue Phase 3 development for INDV-6001 and will seek external business development opportunities for INDV-2000 after its Phase 2 study did not meet the primary endpoint.


Analysis · INDV · Life Sciences

Indivior Pharmaceuticals delivered robust first-quarter results, significantly exceeding expectations and leading to a substantial increase in its full-year 2026 financial guidance. The strong performance of SUBLOCADE, the company's key long-acting injectable for opioid use disorder, drove revenue and EBITDA growth. This positive financial momentum is further supported by disciplined capital allocation, including the execution of a significant share repurchase program and the successful completion of a convertible notes offering to refinance debt. While the company announced the discontinuation of internal development for two pipeline assets (INDV-6001 and INDV-2000), this move is framed as a strategic prioritization, allowing focus on the high-growth SUBLOCADE franchise. The market is likely to view the strong financial performance and capital return favorably, reinforcing the positive sentiment that has driven the stock near its 52-week high.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INDV was trading at $37.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $10.63 to $38.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INDV - Latest Insights

INDV
Nov 02, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.56
Real-time Price: $28.83 info
Change: -$6.73 (-19%) info
Market Cap: $5.989B info
INDV
Oct 29, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $35.25
Real-time Price: $28.83 info
Change: -$6.42 (-18%) info
Market Cap: $5.989B info
INDV
Oct 29, 2026, 8:14 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.51
Real-time Price: $28.83 info
Change: -$7.68 (-21%) info
Market Cap: $5.989B info
INDV
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.44
Real-time Price: $28.83 info
Change: -$5.61 (-16%) info
Market Cap: $5.989B info
INDV
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.44
Real-time Price: $28.83 info
Change: -$5.61 (-16%) info
Market Cap: $5.989B info